American Association for Cancer Research
10780432ccr180252-sup-195902_2_supp_4715515_p82vny.png (179.71 kB)

Supplemental Figure 1 from Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma

Download (179.71 kB)
posted on 2023-03-31, 21:41 authored by Jay Amin, Bo Xu, Shervin Badkhshan, Terrance T. Creighton, Daniel Abbotoy, Christine Murekeyisoni, Kristopher M. Attwood, Thomas Schwaab, Craig Hendler, Michael Petroziello, Charles L. Roche, Eric C. Kauffman

Non-PEER CT peak signal intensity/enhancement values in RO versus ChRCC tumors according to CD117 expression. (A) Net peak enhancement using the delayed/excretory contrast phase relative to the unenhanced phase; (B) Absolute peak signal intensity using an early (arterial/cortical or venous/nephrogenic) contrast phase without subtraction of the unenhanced phase signal intensity; (C) Absolute peak signal intensity using the delayed/excretory contrast phase without subtraction of the unenhanced phase signal intensity.





Purpose: The diagnostic differential for CD117/KIT(+) oncocytic renal tumor biopsies is limited to benign renal oncocytoma versus chromophobe renal cell carcinoma (ChRCC); however, further differentiation is often challenging and requires surgical resection. We investigated clinical variables that might improve preoperative differentiation of CD117(+) renal oncocytoma versus ChRCC to avoid the need for benign tumor resection.Experimental Design: A total of 124 nephrectomy patients from a single institute with 133 renal oncocytoma or ChRCC tumors were studied. Patients from 2003 to 2012 comprised a retrospective cohort to identify clinical/radiographic variables associated with renal oncocytoma versus ChRCC. Prospective validation was performed among consecutive renal oncocytoma/ChRCC tumors resected from 2013 to 2017.Results: Tumor size and younger age were associated with ChRCC, and multifocality with renal oncocytoma; however, the most reliable variable for ChRCC versus renal oncocytoma differentiation was the tumor:cortex peak early-phase enhancement ratio (PEER) using multiphase CT. Among 54 PEER-evaluable tumors in the retrospective cohort [19 CD117(+), 13 CD117(−), 22 CD117-untested], PEER classified each correctly as renal oncocytoma (PEER >0.50) or ChRCC (PEER ≤0.50), except for four misclassified CD117(−) ChRCC variants. Prospective study of PEER confirmed 100% accuracy of renal oncocytoma/ChRCC classification among 22/22 additional CD117(+) tumors. Prospective interobserver reproducibility was excellent for PEER scoring (intraclass correlation coefficient, ICC = 0.97) and perfect for renal oncocytoma/ChRCC assignment (ICC = 1.0).Conclusions: In the largest clinical comparison of renal oncocytoma versus ChRCC to our knowledge, we identified and prospectively validated a reproducible radiographic measure that differentiates CD117(+) renal oncocytoma from ChRCC with potentially 100% accuracy. PEER may allow reliable biopsy-based diagnosis of CD117(+) renal oncocytoma, avoiding the need for diagnostic nephrectomy. Clin Cancer Res; 24(16); 3898–907. ©2018 AACR.

Usage metrics

    Clinical Cancer Research




    Ref. manager